More Than a Muscle Supplement
Creatine is widely known as the go-to supplement for athletes and bodybuilders looking to boost strength and performance. Now, groundbreaking research from UCLA suggests it may have an entirely different — and potentially life-saving — role: helping the immune system mount a stronger attack against cancer.
The study, published in iScience, found that creatine boosts the activity of dendritic cells — specialized immune cells that act as the body's frontline generals, detecting tumors and activating the killer T cells responsible for destroying cancer.
The Discovery
The UCLA team, led by Professor Lili Yang, first noticed that genes responsible for producing the creatine transporter were unusually active in dendritic cells that had infiltrated tumors in mice. When they engineered dendritic cells that couldn't take up creatine, the cells struggled to survive, became less active, and were far less capable of preparing T cells to recognize and attack tumors.
"What this study shows is that creatine doesn't just help the T cells fighting cancer — it also energizes the entire infrastructure that supports and guides them," said Yang, a professor of microbiology, immunology and molecular genetics at UCLA.
Promising Results in Mice
When researchers gave daily creatine injections to mice with melanoma, tumor growth slowed significantly. The treated dendritic cells were more numerous, more active, and released higher levels of chemical signals that attracted additional immune cells into the tumor environment.
Using metabolomics analyses, the scientists found that creatine supplementation increased intracellular ATP levels — the primary energy currency of cells. The researchers compared creatine's role to a rechargeable battery, allowing dendritic cells to store and release energy as needed, even while competing with rapidly growing tumor cells for limited nutrients.
Potential for Human Immunotherapy
The team also tested creatine's effects on human immune cells in the lab. Creatine enhanced the activation of human monocyte-derived dendritic cells — the type commonly used to develop dendritic cell cancer vaccines — and improved their ability to stimulate human T cells against a cancer-associated target.
"The potential we see here is that creatine could be used in two complementary ways: as a supplement to enhance the immune response of patients already receiving immunotherapy, and as a tool to improve the quality of dendritic cell-based vaccines before they're administered," said James Elsten-Brown, a graduate student in Yang's lab and co-first author of the study.
Why This Matters
Today's cancer immunotherapies are designed to activate killer T cells, but only about 20% to 40% of patients experience meaningful benefits. Improving the function of dendritic cells — which coordinate and direct those T cells — could make immunotherapy effective for more people.
"Understanding how to metabolically support dendritic cells is about supporting the entire anti-tumor response, not just the killer T cells at the end of it," said Elliot Kang, a co-first author of the study.
What's Next
The researchers caution that the work remains at an early stage. The experiments were conducted in mice and human cells grown in the laboratory, not in cancer patients, so the results should not be interpreted as evidence that creatine supplements improve cancer treatment in people just yet.
Although creatine monohydrate has been widely used for decades and is generally considered safe at recommended doses, anyone receiving cancer treatment should consult their physician before adding any supplement to their routine.
The next step will be prospective clinical trials to determine whether creatine supplementation can improve outcomes for patients undergoing cancer immunotherapy.
